Medicine and Dentistry
Cerebral Hemorrhage
100%
Bleeding
65%
Minimally Invasive Surgery
39%
Alteplase
38%
Placebo
34%
Evacuation
34%
Apoplexy
32%
Clinical Trial
31%
Blood Clot Lysis
28%
Cavernous Hemangioma
26%
Heart Surgery
24%
Asthma
24%
Biological Marker
23%
Randomized Controlled Trial
23%
Otorhinolaryngology
22%
Modified Rankin Scale
21%
Pediatrics
20%
Computer Assisted Tomography
19%
Odds Ratio
19%
Sickle-Cell Disease
18%
Quantitative Susceptibility Mapping
18%
Drug Therapy
16%
Toddlers
16%
Symptom
15%
Patient Experience
14%
Disease
13%
Hematoma
13%
Body Mass Index
12%
Preventive Medicine
12%
Pediatric Otolaryngology
12%
Achondroplasia
12%
Bryostatin
12%
Program Director
12%
Inflammatory Bowel Disease
12%
Postmenopause
12%
Congenital Malformation
12%
Brain Surgery
12%
Electronic Health Record
12%
Alzheimer's Disease
12%
Limb
11%
Surgeon
11%
Emergency Department
11%
Patient Satisfaction
11%
Primary Health Care
11%
Surgery
10%
Quality of Life
10%
Medical Care
10%
Logistic Regression Analysis
9%
Magnetic Resonance Imaging
9%
Ambulatory Care in General Pediatrics
9%
Keyphrases
Intracerebral Hemorrhage
54%
Intraventricular Hemorrhage
40%
Children with Asthma
27%
Trial Readiness
24%
Symptomatic Hemorrhage
24%
Modified Rankin Scale
22%
Minimally Invasive Surgery
21%
Computed Tomography
20%
Meta-analysis
18%
Sickle Cell Disease
18%
MISTIE
17%
Caregivers
17%
Clinical Outcomes
16%
Evacuation
16%
Odds Ratio
15%
Functional Outcome
15%
Hemorrhage Volume
15%
Inflammatory Bowel Disease
14%
Thrombolysis
14%
Placebo-controlled
13%
Placebo
13%
Spontaneous Intracerebral Hemorrhage
13%
Multicenter Randomized Controlled Trial
13%
Pediatric
12%
Cavernous Malformation
12%
Preventive Care
12%
Hematologist
12%
Quantitative Susceptibility Mapping
12%
Cardiac Surgery
12%
Cavernous Angioma
12%
Spontaneous Intracranial Hemorrhage
12%
Intracranial Surgery
12%
Autism Spectrum Disorder
12%
Cardiomyopathy
12%
Feasibility pilot
12%
Confidence Interval
11%
Crohn's Disease
11%
Brain Injury
9%
Supratentorial
9%
Inner child
9%
Asthma
9%
Catheter Placement
9%
Phase II Trial
9%
Young children
9%
Alteplase
9%
Cotinine
9%
Medicaid
9%
Attenuation
8%
Clot Lysis
8%
Generalist
8%